VK2735 for Weight Management Phase 3

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT07104500
StatusActive not recruiting
PhasePhase 3
SponsorViking Therapeutics, Inc.
Enrollment4,500 participants
DesignInterventional, Randomized, Parallel, Masking: Triple
ConditionsWeight Loss
InterventionsVK2735
StartJun 23, 2025
Primary completionJul 1, 2027
Study completionAug 1, 2027
Results postedNot yet
Registry last updatedNov 24, 2025

Compounds on this site that cite this trial

What the registry says the trial is about

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment78 Weeks

1 secondary outcome also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.

Share thisFacebookXEmail